ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

ArdansChemistry set to unveil new diabetic friendly cold and allergy medicine

Nashville, Tennessee, United States - 08-09-2022 (PR Distribution™) -

There's a new player in the consumer goods market, and they're on a mission to make life simpler for diabetics.

Today, Bordeaux Laboratories is announcing the pre-launch of its ArdansChemistry brand of diabetic friendly cold and allergy medicine. The brand specializes in products that are free of ingredients and can affect blood glucose, blood pressure, and hormones. Their cold and allergy medicines are designed to be safe for diabetics to take and are effective in treating both colds and allergies. The solutions contain clean ingredients with a couple that are very low on the glucose index to assure a pleasurable flavor but no effect on blood glucose. This is essential for those with diabetes who want to fight their sickness without harming their health even more. Chewable tablets are easy to take and don't require any water, making them perfect for when you're not feeling your best.

Living with diabetes is a constant balancing act. On one hand, you need to carefully monitor your blood sugar levels and make sure that you are taking the right amount of insulin. On the other hand, you also need to pay attention to your diet and lifestyle, making sure that you are getting enough exercise and eating healthy foods. It can be a lot to keep track of, and even a small change can have a big impact on your health. And even today, the market is flooded with solutions that contain sugar, parabens, alcohol, and more artificial ingredients that have been proven not to be healthy to consumers - especially those with diabetes.

ArdansChemistry is committed to providing healthy and safe solutions for their customers. Their experience and care for their customers shines through in every product they create. "My mother passed away from diabetic ketoacidosis in July 2008. Watching her struggle with Type 1 diabetes I learned that managing diabetes isn't just about insulin and pricking fingers, it's about everything. There is so much that we take for granted whether it be the over the counter medicine we take to the toothpaste we use. This startup is dedicated to serving a community of people that exude perseverance and discipline every single day" said Don Merriman, Founder & CEO of Bordeaux Laboratories, Inc.

According to the Centers for Disease Control and Prevention, nearly 10% of Americans have diabetes. That's more than 30 million people. And the number is only expected to grow in the coming years. Yet, despite this large and growing population, the diabetic market has been largely ignored by companies in the past. However, that appears to be changing. 

Bordeaux Laboratories recently conducted a study of 300 diabetics and found that 77% of them felt that there was a need for products specifically designed for their condition. With this launch, Bordeaux Laboratories is poised to make a positive impact on the lives of those with diabetes and allergies. In addition, the brand is committed to offering a competitive price point in order to make its product accessible to as many people as possible. The product is now available for preorder on Amazon and will officially launch in October 2022.

ArdansChemistry is now taking pre-orders on their website https://ardans.co . You may reach out to help@ardans.co  for more questions. 

Follow ArdansChemistry on Instagram with IG handle @ardans_us

Media Contacts:

Company Name: ArdansChemistry
Full Name: Don Merriman
Phone: n/a
Email Address: Send Email
Website: https://www.ardans.co

For the original news story, please visit https://www.prdistribution.com/news/ardanschemistry-set-to-unveil-new-diabetic-friendly-cold-and-allergy-medicine/9245875.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.